# Takeda Pharmaceutical Company Limited share price today (Takeda Pharmaceutical Company Limited, TAK)

> Takeda Pharmaceutical Company Limited's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. TAK · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/tak

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from fewer quarters than usual
- Price: $20.75 (+54.4% in a year)
- P/E: 255.6×, against its own history
- Revenue (Jun 2026): JPY 1,220 B (+10.2% on a year ago)
- Profit (Jun 2026): JPY 113 B (−8.9% on a year ago)
- Operating margin: 16.4% (+1.1 points on a year ago)
- ROE: −2%, FY26
- ROIC: 6.2%, against a 4.3% cost of capital: +1.9 points

Biggest thing to watch: the price has already been rising for 19 weeks, so timing is the risk more than the business. ## What is the Takeda Pharmaceutical Company Limited share price today? Takeda Pharmaceutical Company Limited's share price was $20.75 at the close on 3 November 2026. It has been rising for 19 weeks. That is 17.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $14 and $21, and at that close it sat 98% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 14 weeks in a row. Over the last 10 years the share price moved −3% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Takeda Pharmaceutical Company Limited pay? Takeda Pharmaceutical Company Limited declared JPY 100.00 per local share for Mar 2026, and JPY 396.00 over the last four reported quarters. It reports in Japanese yen, and one US-listed share can stand for several local shares, so we do not set this against the dollar price or show a yield. ## Which stock lists is Takeda Pharmaceutical Company Limited on? Takeda Pharmaceutical Company Limited is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Takeda Pharmaceutical Company Limited profitable? Takeda Pharmaceutical Company Limited earned JPY 113 B of net profit in the Jun 2026 quarter, −8.9% on the same quarter a year earlier. The full FY26 year was a loss of JPY 152 B. That is 9.3% of the quarter's revenue. The same quarter a year earlier earned JPY 124 B. 5 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was −JPY 152 B (−241.2% on the year before). Why profit moved: revenue changed +10.2% on a year earlier and the margin moved +1.1 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +71.3% and revenue +3.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. This company reports in Japanese yen, not US dollars, so the money charts are left out here. The figures in the text are in that currency (JPY); nothing is converted. ## How much revenue does Takeda Pharmaceutical Company Limited make, and is it growing? Takeda Pharmaceutical Company Limited reported JPY 1,220 B of revenue in the Jun 2026 quarter, +10.2% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 4 years it has grown 6.0% a year on average. The last full year, FY26, came in at JPY 4,506 B. The last four reported quarters add to JPY 4,619 B. FY26 revenue was JPY 4,506 B, −1.7% on the year before. Recent pace: the last four quarters grew +3.2% on average, against 6.0% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +3.1%, against +2.3% a year over the last 8 quarters (stabilising). This company reports in Japanese yen, not US dollars, so the money charts are left out here. The figures in the text are in that currency (JPY); nothing is converted. ## How much of its sales does Takeda Pharmaceutical Company Limited keep? Takeda Pharmaceutical Company Limited's operating margin was 16.4% in the Jun 2026 quarter, 1.1 percentage points higher than the same quarter a year ago. Across 5 years it has been between 11.8% and 16.8%. The latest quarter is within that range. Why the margin moved: operating margin changed +1.1 percentage points on the year while gross margin changed +1.5 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Takeda Pharmaceutical Company Limited's profit turning into cash? Over the last 3 years, 483% of Takeda Pharmaceutical Company Limited's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in JPY 1,041 B of operating cash against −JPY 152 B of profit. After JPY 176 B of spending on assets, JPY 865 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. This company reports in Japanese yen, not US dollars, so the money charts are left out here. The figures in the text are in that currency (JPY); nothing is converted. ## Where does Takeda Pharmaceutical Company Limited's cash go? Takeda Pharmaceutical Company Limited does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent JPY 552 B on assets over the last 3 years. Averaged over those years that is 4.1% of FY26 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: JPY 552 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. This company reports in Japanese yen, not US dollars, so the money charts are left out here. The figures in the text are in that currency (JPY); nothing is converted. ## What is Takeda Pharmaceutical Company Limited's P/E ratio, and how does it compare with its own history? Takeda Pharmaceutical Company Limited's P/E is 255.6×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Takeda Pharmaceutical Company Limited business getting better or worse? Takeda Pharmaceutical Company Limited's business is giving mixed signals. Revenue growth is rising from its low at +3.1% while profit growth is falling at −219.4%, so the lines disagree and each one tells part of the story. This is based on 12 quarters of 3 measures, with some gaps. Why it matters: when the lines disagree, each line above matters more than any single label. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Takeda Pharmaceutical Company Limited earn on its capital? Takeda Pharmaceutical Company Limited earned a ROE of −2% in FY26. Its return on capital used (ROIC) is 1.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a −3.4% net margin and 0.29× asset turnover (sales divided by assets). Why the return is what it is (FY26): a −3.4% net margin × 0.29× asset turnover × 2.09× leverage (assets divided by equity) ≈ −2.1% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 6.2% − 4.3% = +1.9 percentage points. The 4.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 6.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 5.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Takeda Pharmaceutical Company Limited have too much debt? Takeda Pharmaceutical Company Limited has total debt of JPY 5,536 B against shareholder equity of JPY 7,559 B as of Jun 2026, so its debt is 0.73× its equity. Year by year, that ratio went from 0.85 in FY22 to 0.74 in FY26. Keep that borrowing in mind when reading the returns on this page. This company reports in Japanese yen, not US dollars, so the money charts are left out here. The figures in the text are in that currency (JPY); nothing is converted. ## What is the Takeda Pharmaceutical Company Limited shareholding pattern? 0.2% of Takeda Pharmaceutical Company Limited's tradable shares are in short positions, which are bets that the price will fall, so very few traders are betting against this stock. At normal trading volumes, closing those positions would take about 1.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Takeda Pharmaceutical Company Limited from balance-sheet trouble? For Takeda Pharmaceutical Company Limited, the Z-score is 1.21. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.21 is inside the danger zone, so the balance sheet is a real risk. ## How does Takeda Pharmaceutical Company Limited rank in its industry? There is no score against its industry: Takeda Pharmaceutical Company Limited is not among the largest members shown in this industry comparison for Drug Manufacturers - Specialty & Generic. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Takeda Pharmaceutical Company Limited compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Takeda Pharmaceutical Company Limited in size? Takeda Pharmaceutical Company Limited is the largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 3 November 2026). It is the largest. Just below it: Teva Pharmaceutical Industries, Haleon plc, Zoetis Inc., United Therapeutics Corporation, Viatris Inc. and Neurocrine Biosciences, Inc. ### Drug Manufacturers - Specialty & Generic companies close in size

1. Takeda Pharmaceutical Company Limited $67.3 billion
2. [Teva Pharmaceutical Industries Limited](https://www.sectoralpha.in/us/stocks/teva) $48.8 billion
3. [Haleon plc](https://www.sectoralpha.in/us/stocks/hln) $38.8 billion
4. [Zoetis Inc.](https://www.sectoralpha.in/us/stocks/zts) $34.3 billion
5. [United Therapeutics Corporation](https://www.sectoralpha.in/us/stocks/uthr) $25.8 billion
6. [Viatris Inc.](https://www.sectoralpha.in/us/stocks/vtrs) $21.7 billion
7. [Neurocrine Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/nbix) $16.8 billion

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [Hewlett Packard Enterprise Company](https://www.sectoralpha.in/us/stocks/hpe) $68 billion · Communication Equipment
2. [Digital Realty Trust, Inc.](https://www.sectoralpha.in/us/stocks/dlr) $67.7 billion · REIT - Specialty
3. Takeda Pharmaceutical Company Limited $67.3 billion
4. [TransDigm Group Incorporated](https://www.sectoralpha.in/us/stocks/tdg) $67.1 billion · Aerospace & Defense
5. [The Allstate Corporation](https://www.sectoralpha.in/us/stocks/all) $66.8 billion · Insurance - Property & Casualty

## What else do people ask about Takeda Pharmaceutical Company Limited? ### What were Takeda Pharmaceutical Company Limited Limited's latest quarterly results? Takeda Pharmaceutical Company Limited reported revenue of JPY 1,220 B and net profit of JPY 113 B for the Jun 2026 quarter. Revenue rose 10.2% and profit fell 8.9% compared with a year earlier. The operating margin was 16.4%, 1.1 percentage points higher than a year earlier (as of 3 November 2026). ### What is Takeda Pharmaceutical Company Limited Limited's market cap? Takeda Pharmaceutical Company Limited's market capitalisation is $67.3 B at a stock price of $20.75. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Takeda Pharmaceutical Company Limited Limited performing? Takeda Pharmaceutical Company Limited's share price has been rising for 19 weeks. In its latest quarter, revenue rose 10.2% and profit fell 8.9% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 14 weeks running (as of 3 November 2026). ### Will Takeda Pharmaceutical Company Limited Limited's stock price go up? This page does not forecast Takeda Pharmaceutical Company Limited's stock price. What it shows instead: the stock price is $20.75, and it has been rising for 19 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Does Takeda Pharmaceutical Company Limited Limited have too much debt? Takeda Pharmaceutical Company Limited has a moderate amount of debt: its debt is 0.72× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Is Takeda Pharmaceutical Company Limited Limited's profit real cash? Yes, over the last 3 years, 483% of Takeda Pharmaceutical Company Limited's reported profit came in as cash from operations. The latest year was lower at -683%, so the trend is worth watching. In FY26, operating cash was JPY 1,041 B against reported profit of −JPY 152 B. Most of that cash then goes into building new capacity. These are yearly figures (as of 3 November 2026). ### Where is Takeda Pharmaceutical Company Limited Limited in its business cycle? Takeda Pharmaceutical Company Limited's FY26 operating margin was 13.5%, against a 5-year range of 11.8% to 16.8%: the middle of its own range, neither a peak nor a low. The latest quarter was 16.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Takeda Pharmaceutical Company Limited Limited story? Biggest thing to watch: the price has already been rising for 19 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Takeda Pharmaceutical Company Limited Limited a stock worth studying right now? What the numbers show: Takeda Pharmaceutical Company Limited's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.